Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Zai Lab Ltd (9688)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
13.00 +0.44    +3.50%
30/04 - Closed. Currency in HKD ( Disclaimer )
  • Volume: 4,273,600
  • Bid/Ask: 12.88 / 13.00
  • Day's Range: 12.56 - 13.00
Type:  Equity
Market:  Hong Kong
ISIN:  KYG9887T1168 
Zai Lab 13.00 +0.44 +3.50%

Zai Lab Company Profile

 
Read the Zai Lab Ltd company profile to learn more about the business and the management team. View Zai Lab Ltd facts about employee data, company products and services, and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

2036

Equity Type

ORD

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

Contact Information

Address Jinchuang Plaza Building 1, Fourth Floor
4560 Jinke Road Pudong Shanghai, 201210
China
Phone 86 21 6163 2588
Fax -

Top Executives

Name Age Since Title
Ying Du 55 2014 Founder, Chairperson & CEO
Peter Wirth 71 2017 Independent Director
Scott W. Morrison 64 2021 Independent Director
Leon O. Moulder 65 2020 Independent Director
John D. Diekman 80 2017 Lead Independent Director
Wing Yu Leung 53 2014 Independent Director
William David Lis 59 2018 Independent Director
Neal Rosen 73 2016 Member of Scientific Advisory Board
Kaixian Chen 77 2018 Independent Director
Richard B. Gaynor 73 2021 Independent Director
Timothy A. Yap 48 2019 Member of Scientific Advisory Board
Lieping Chen 66 2019 Member of Scientific Advisory Board
Alex A. Adjei 67 - Member of Scientific Advisory Board
Michel Vounatsos 61 2023 Independent Director
Yingyu Liang 52 2014 Independent Director
Wing-Yu Leung 53 2014 Independent Director
Wing-Yu Leung 53 2014 Independent Director
Wing-Yu Leung 53 2014 Independent Director
Wing-Yu Leung 53 2014 Independent Director
Wing-Yu Leung 53 2014 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

9688 Price Commentary

Write your thoughts about Zai Lab Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email